Latest Breaking News On - Fda approval of glofitamab - Page 1 : comparemela.com

Carmelo Carlo-Stella, MD, PhD, discusses the FDA approval of glofitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy.

Carmelo carlo stellaDepartment of oncologyDepartment of biomedical sciencesHumanitas universityHumanitas research hospitalBiomedical sciencesResearch hospitalFda approval of glofitamabPatients with relapsed refractory diffuse largeb cell lymphomaPhase 1 2 np30179 trial